BioCryst Pharmaceuticals, Inc. (BCRX) Zooms Higher on Zika Data

BioCryst Pharmaceuticals, Inc. (BCRX) is rallying on Zika drug data, possibly to the delight of recent option buyers

Mar 7, 2016 at 12:33 PM
facebook X logo linkedin


Drugmaker BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is surging 22.7% to $3.17 today, after announcing that a preclinical study in mice showed promising results of an antiviral treatment for the Zika virus. The company is presenting these trial results at a meeting of the World Health Organization (WHO) in Geneva, Switzerland, this week. And while the stock had a rough start to 2016, a recent crop of option buyers could be cheering today's rally.

BCRX is down 69% year-to-date. Ugly trial data from the company's OPuS-2 treatment for a rare genetic disorder clobbered the shares in early February, sending them down 71%  in a single session. A round of bearish brokerage notes -- and a drop to two-year lows -- followed, but the equity has added roughly 30% so far in March.

However, Wall Street remains wary. Of the nine brokerage firms following the stock, only three rate it better than a "hold." And short interest on BCRX is elevated, representing more than 15% of the security's total available float.

Option traders, however, have picked up BCRX calls over puts at a faster-than-usual clip during the past two weeks, albeit at relatively low absolute volumes. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 10-day call/put volume ratio stands at 196 -- indicating that traders have overwhelmingly bought to open BCRX calls over puts. Moreover, this ratio is higher than 97% of all readings taken in the past year. However, considering the aforementioned short interest, it's possible that some of that call buying -- particularly at out-of-the-money strikes -- could be attributable to shorts looking for an options hedge.

Whatever the motive, this could be an enticing time to pick up BCRX's short-term options. The stock has a Schaeffer's Volatility Index (SVI) of 150% -- in the mild 25th percentile of its annual range. That means near-term premium on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) options can be bought relatively cheaply at the moment.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI